Raymond James Financial Services Advisors Inc. Takes $207,000 Position in Exscientia plc (NASDAQ:EXAI)

Raymond James Financial Services Advisors Inc. acquired a new stake in Exscientia plc (NASDAQ:EXAI) in the 4th quarter, HoldingsChannel reports. The fund acquired 32,220 shares of the company’s stock, valued at approximately $207,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Exchange Traded Concepts LLC boosted its stake in shares of Exscientia by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 27,275 shares of the company’s stock valued at $175,000 after purchasing an additional 6,916 shares during the period. Banque Pictet & Cie SA purchased a new position in shares of Exscientia in the third quarter valued at approximately $1,040,000. Federated Hermes Inc. purchased a new position in shares of Exscientia in the third quarter valued at approximately $362,000. Rathbones Group PLC acquired a new stake in Exscientia in the third quarter valued at approximately $47,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in Exscientia in the third quarter valued at approximately $344,000. Hedge funds and other institutional investors own 41.58% of the company’s stock.

Wall Street Analysts Forecast Growth

EXAI has been the topic of several analyst reports. Bank of America cut shares of Exscientia from a “buy” rating to a “neutral” rating and reduced their target price for the company from $11.00 to $9.00 in a report on Friday, January 5th. Morgan Stanley reissued an “equal weight” rating and set a $7.00 price objective on shares of Exscientia in a report on Monday.

Exscientia Stock Down 5.7 %

EXAI stock opened at $4.13 on Thursday. The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.05. Exscientia plc has a twelve month low of $4.13 and a twelve month high of $9.12. The company’s 50 day moving average is $5.73 and its two-hundred day moving average is $5.85. The stock has a market cap of $499.28 million, a P/E ratio of -2.79 and a beta of 0.78.

Exscientia (NASDAQ:EXAI) last announced its earnings results on Thursday, March 21st. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. The business had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $41.63 million. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. Research analysts expect that Exscientia plc will post -1.76 earnings per share for the current fiscal year.

Exscientia Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.